Epigenetic control of lipid metabolism in adaptive drug resistance

Cancer drug resistance is a major hindrance for successful anti-tumoral treatment with about half of cancer patients succumbing to their disease. Changes in the epigenome and lipid composition of cancer cells largely contribute to drug resistance. In collaboration with the Frazer Institute, The University of Queensland, Brisbane, Australia, Drs Koeberle and Schaider investigate novel avenues to overcome cancer drug resistance by focusing on druggable targets at the intersection of epigenetic and lipid metabolic changes. This approach aims to prevent the development of drug tolerance and subsequent disease recurrence.